IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

Study Overview
=================
Brief Summary
-----------------
Many laboratory markers can be measured for assessment of Lupus activity as aberrant manufacturing and imbalance of the cytokines of T-helper cell which already have been implicated within autoimmunity pathogenesis as IL-18 and IL-10 levels are usually elevated in lupus sufferers and correlated with SLEDAI score IL-17 has been linked to immune-mediated organ damage in several autoimmune diseases and recently it has been linked to pathogenesis of a murine model of lupus and human lupus Diverse cytokine abnormalities which common in lupus patients may skew T cells differentiation into IL-17-producing CD4+ and double negative T cells. This could promote the autoimmune process by activation of immune cells &stimulation of proliferation of B-cell and production of antibody

Official Title
-----------------
IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

Conditions
-----------------
Systemic Lupus Erythematosus

Intervention / Treatment
-----------------
* Diagnostic Test: Serum level of IL-17


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SLE will be diagnosed according to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE Age ≥ 18 years. Patients who are able and willing to give written informed consent Exclusion Criteria: -Any other autoimmune disease rather than SLE. - Systemic diseases Malignancy pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases with SLE<br>110 patients with SLE will be divided to : 40 patients with lupus nephritis 40 patients interstitial lung disease 30 SLE patients without internal organ affection) | Diagnostic Test: Serum level of IL-17<br>* Measurement of serum level of IL-17 : To explore the role of IL-17 in systemic lupus erythematosus To determine the relation between IL-17 and lupus disease activity To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)<br>|
| control group<br>30 sex and age matched healthy individuals as a control group | Diagnostic Test: Serum level of IL-17<br>* Measurement of serum level of IL-17 : To explore the role of IL-17 in systemic lupus erythematosus To determine the relation between IL-17 and lupus disease activity To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SLE disease activity index (SLEDAI) | • Assessment of the disease activity in the patients will be done by using the SLE disease activity index (SLEDAI). It potentially measures reversible manifestations of the underlying inflammatory disease process. The scale includes24 weighted attribute grouped into 9 domains. The final score is the sum of all attributed scores. No activity 0 mild activity: 1-5 moderate activity: 6- 1 0 high activity : 1 1 - 1 9 very high > 20 | 18 Months |